EGFR and lung adenocarcinoma: Karachaliou et al. found that knockdown of Orphan receptor 1 (ROR1) could inhibit the growth of NCI-H1975 cells [harboring EGFR L858R and T790M mutations (24)] via the ROR1/MEK/ERK signaling pathway, indicating the potential of ROR1 as therapeutic target for EGFR positive lung adenocarcinoma (LUAD) (26).